Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | TOP2A | P11388 | 1/20 | 0.34 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2933107 | 0.72 | CES2 (0.35) | CES2CES1TOP2ATOP2B | |
| SCHEMBL1336686 | 0.70 | — | — | |
| SCHEMBL2227027 | 0.69 | — | — | |
| SCHEMBL13893272 | 0.68 | CES2 (0.35) | CES2CES1TOP2ATOP2B | |
| SCHEMBL4382702 | 0.68 | CES2 (0.35) | CES2CES1TOP2ATOP2B | |
| SCHEMBL15792152 | 0.67 | CYP11B2 (0.30) | — | |
| SCHEMBL4370997 | 0.67 | CES2 (0.34) | CES2CES1TOP2ATOP2B | |
| SCHEMBL2225410 | 0.67 | WRN (0.36) | CES2CES1TOP2ATOP2B | |
| SCHEMBL4379583 | 0.67 | CES2 (0.34) | CES2CES1TOP2ATOP2B | |
| SCHEMBL25997575 | 0.67 | TOP2A (0.37) | CES2CES1TOP2ATOP2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595239-B2 | Substituted isoxazoline derivatives | BASF SE (DE) | 2026-04-07 | — | — | US | disclosed |
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| EP-4291551-B1 | SUBSTITUTED ISOXAZOLINE DERIVATIVES | BASF SE (DE) | 2025-08-13 | — | — | EP | disclosed |
| US-20240140917-A1 | SUBSTITUTED ISOXAZOLINE DERIVATIVES | BASF SE (DE) | 2024-05-02 | — | — | US | disclosed |
| EP-4291551-A1 | SUBSTITUTED ISOXAZOLINE DERIVATIVES | BASF SE (DE) | 2023-12-20 | — | — | EP | disclosed |
| WO-2023183405-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2022171472-A1 | SUBSTITUTED ISOXAZOLINE DERIVATIVES | BASF SE (DE) | 2022-08-18 | — | — | WO | disclosed |
| EP-3110812-B1 | ANTI-AMYLOID COMPOUNDS CONTAINING BENZOFURAZAN | TREVENTIS CORP (US) | 2019-04-10 | — | — | EP | disclosed |
| US-9938249-B2 | Anti-amyloid compounds containing benzofurazan | TREVENTIS CORPORATION (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170174641-A1 | ANTI-AMYLOID COMPOUNDS CONTAINING BENZOFURAZAN | TREVENTIS CORPORATION (US) | 2017-06-22 | — | — | US | disclosed |
| WO-2011088181-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| US-7799825-B2 | Thiophene and thiazole substituted trifluoroethanone derivatives as histone deacetylase (HDAC) inhibitors | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2010-09-21 | — | — | US | disclosed |
| US-7799825-B2 | Thiophene and thiazole substituted trifluoroethanone derivatives as histone deacetylase (HDAC) inhibitors | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2010-09-21 | — | — | US | disclosed |
| US-7799825-B2 | Thiophene and thiazole substituted trifluoroethanone derivatives as histone deacetylase (HDAC) inhibitors | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2010-09-21 | — | — | US | disclosed |
| US-20090076101-A1 | Thiophene and Thiazole Substituted Trifluoroethanone Derivatives as Histone Deacetylase (HDAC) Inhibitors | MSD ITALIA S.R.L. (IT) | 2009-03-19 | — | — | US | disclosed |
| US-20090076101-A1 | Thiophene and Thiazole Substituted Trifluoroethanone Derivatives as Histone Deacetylase (HDAC) Inhibitors | MSD ITALIA S.R.L. (IT) | 2009-03-19 | — | — | US | disclosed |
| US-20090076101-A1 | Thiophene and Thiazole Substituted Trifluoroethanone Derivatives as Histone Deacetylase (HDAC) Inhibitors | MSD ITALIA S.R.L. (IT) | 2009-03-19 | — | — | US | disclosed |
| EP-1987024-A1 | THIOPHENE AND THIAZOLE SUBSTITUTED TRIFLUOROETHANONE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | Istituto di Ricerche di Biologia Molecolare P. Angeletti (IT) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007093827-A1 | THIOPHENE AND THIAZOLE SUBSTITUTED TRIFLUOROETHANONE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007093827-A1 | THIOPHENE AND THIAZOLE SUBSTITUTED TRIFLUOROETHANONE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595239-B2 | Substituted isoxazoline derivatives | CBR3, ADRA2C, CYP4Z1 | CES2 403/4885CES1 606/4885TOP2A 1038/4885 |
| US-20240140917-A1 | SUBSTITUTED ISOXAZOLINE DERIVATIVES | CYP4X1, PRDX5, PRDX1 | CES2 1811/4885CES1 3087/4885TOP2A 751/4885 |
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C5, C1S, C9 | CES2 1957/4885CES1 413/4885TOP2A 4398/4885 |
| US-20090076101-A1 | Thiophene and Thiazole Substituted Trifluoroethanone Derivatives as Histone Deacetylase (HDAC) Inhibitors | HDAC1, HDAC4, HDAC7 | CES2 3305/4885CES1 1678/4885TOP2A 513/4885 |
| US-20170174641-A1 | ANTI-AMYLOID COMPOUNDS CONTAINING BENZOFURAZAN | PRNP, PSEN1, APP | CES2 3896/4885CES1 2735/4885TOP2A 2062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.